Category: Clinical Trial
Clinical Trial market research reports by DelveInsight
-
KRAS Inhibitors - Market Size, Target Population, Competitive Landscape & Market Forecast - 2034
Key Highlights Among the 7MM, the United States captured the highest KRAS inhibitors market size in 2023, accounting for nearly 70% of the total KRAS Inhibitor market share. Among the approved KRAS Inhibitor therapies in the United States, KRAZATI is expected to have the edge over LUMAKRAS in revenu ... Read More
-
Oligometastatic Disease - Market Insights, Epidemiology, and Market Forecast - 2034
Key Highlights According to DelveInsight’s patient-based forecasting model, the oligometastatic disease market size in the 7MM was around USD 1,900 million in 2023, which is expected to significantly increase over the forecast period (2024-2034), owing to an increase in the cases and the launch of n ... Read More
-
Metastatic Colorectal Cancer - Pipeline Insight, 2025
DelveInsight’s, “Metastatic Colorectal Cancer - Pipeline Insight, 2025” report provides comprehensive insights about 150+ companies and 180+ pipeline drugs in Metastatic Colorectal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It ... Read More
-
Microbiome Disease- Pipeline Insight, 2025
DelveInsight’s, “Microbiome Disease- Pipeline Insight, 2025” report provides comprehensive insights about 140+ companies and 180+ pipeline drugs in Microbiome Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the thera ... Read More
-
Janus Kinase (JAK) Inhibitor- Pipeline Insight, 2025
DelveInsight’s, “Janus Kinase (JAK) Inhibitor- Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Janus Kinase (JAK) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It als ... Read More
-
Adenosine A3 Receptor Agonist - Pipeline Insight, 2025
“Adenosine A3 Receptor Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Adenosine A3 Receptor Agonist development. The report provides detailed coverage of the pipeline landsca ... Read More
-
Akt1 Inhibitor - Pipeline Insight, 2025
“Akt1 Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Akt1 Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of actio ... Read More
-
Aldose Reductase Inhibitor - Pipeline Insight, 2025
“Aldose Reductase Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Aldose Reductase Inhibitor development. The report provides detailed coverage of the pipeline landscape for ... Read More
-
Alpha v Beta 3/5/6 Integrin Antagonist - Pipeline Insight, 2025
“Alpha v Beta 3/5/6 Integrin Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Alpha v Beta 3/5/6 Integrin Antagonist development. The report provides detailed coverage of th ... Read More
-
Alpha v Beta 3 Integrin Antagonist - Pipeline Insight, 2025
“Alpha v Beta 3 Integrin Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Alpha v Beta 3 Integrin Antagonist development. The report provides detailed coverage of the pipeli ... Read More
-
AMPA Receptor Antagonist - Pipeline Insight, 2025
“AMPA Receptor Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across AMPA Receptor Antagonist development. The report provides detailed coverage of the pipeline landscape for thi ... Read More
-
Sigma Receptor Agonist - Pipeline Insight, 2025
“Sigma Receptor Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Sigma Receptor Agonist development. The report provides detailed coverage of the pipeline landscape for this me ... Read More
-
Type 4 cyclic nucleotide phosphodiesterase inhibitors - Pipeline Insight, 2025
DelveInsight’s, “Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors pipeline landscape. It covers the pipeline drug profiles, includ ... Read More
-
Murine Double Minute 2 (MDM2) Inhibitor - Pipeline Insight, 2025
“Murine Double Minute 2 (MDM2) Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Murine Double Minute 2 (MDM2) Inhibitor development. The report provides detailed coverage of ... Read More
-
Aldosterone Antagonist - Pipeline Insight, 2025
“Aldosterone Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Aldosterone Antagonist development. The report provides detailed coverage of the pipeline landscape for this me ... Read More
-
Alpha-1 Antagonist - Pipeline Insight, 2025
“Alpha-1 Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Alpha-1 Antagonist development. The report provides detailed coverage of the pipeline landscape for this mechanism ... Read More
-
Angiotensin Receptor Agonist - Pipeline Insight, 2025
“Angiotensin Receptor Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Angiotensin Receptor Agonist development. The report provides detailed coverage of the pipeline landscape ... Read More
-
Anti-Lymphotoxin - Pipeline Insight, 2025
“Anti-Lymphotoxin - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-Lymphotoxin development. The report provides detailed coverage of the pipeline landscape for this mechanism of a ... Read More
-
Apolipoprotein B (ApoB) Inhibitor - Pipeline Insight, 2025
“Apolipoprotein B (ApoB) Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Apolipoprotein B (ApoB) Inhibitor development. The report provides detailed coverage of the pipeline ... Read More
-
Kv1.3 Potassium Channel Blockers - Pipeline Insight, 2025
“Kv1.3 Potassium Channel Blockers - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Kv1.3 Potassium Channel Blockers development. The report provides detailed coverage of the pipeline l ... Read More
-
Transient Receptor Potential Cation Channel, Subfamily M, Member 8 (TRPM8) Antagonist - Pipeline Insight, 2025
“Transient Receptor Potential Cation Channel, Subfamily M, Member 8 (TRPM8) Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Transient Receptor Potential Cation Channel, Sub ... Read More
-
Potassium channel antagonists - Pipeline Insight, 2025
DelveInsight’s, “Potassium channel antagonists - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Potassium channel antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It ... Read More
-
B-cell Lymphoma- Pipeline Insight, 2025
DelveInsight’s, “B-cell Lymphoma- Pipeline Insight, 2025” report provides comprehensive insights about 295+ companies and 300+ pipeline drugs in B-cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutic ... Read More
-
Diabetic Nephropathy- Pipeline Insight, 2025
DelveInsight’s, “Diabetic Nephropathy- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Diabetic Nephropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the the ... Read More
-
Huntington’s Disease - Pipeline Insight, 2025
DelveInsight’s, “Huntington’s Disease - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Huntington’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the t ... Read More
Research Assistance
